Expense guidance includes the expenses related to executing and completing the NEPHRO CRRT registration trial before the end of the year.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLPH:
- Talphera files to sell 3.41M shares of common stock for holders
- Talphera, Inc. Earnings Call: Progress Amid Challenges
- Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating
- Talphera Reports 2024 Financial Results and Study Update
- Talphera reports Q4 EPS (7c) vs. (25c) last year